Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
Bond DA, Huang Y, Ruppert AS, Walker AR, Dotson EK, Roddy J, Blum KA, Christian BA
Leuk Lymphoma 58 1589-1597 01/01/2017
The initial dose of bendamustine, an alkylating agent used in treating indolent lymphoma (iNHL) and mantle cell lymphoma, is variable in clinical practice. 134 patients treated with bendamustine and rituximab were evaluated for starting dosage, patient characteristics, toxicities, and clinical outcome. The starting dosage ranged from 50 to 90 mg/mFull Text